Free accessResearch articleFirst published online 2003-8
Recombinant Activated Factor VII for Exsanguinating Haemorrhage Post Bilateral Lung Transplantation for Extra-corporeal Lung Support-dependent Respiratory Failure
Following three weeks of extracorporeal lung support for acute respiratory distress syndrome, a 15-year-old male underwent bilateral lung transplantation. This procedure was complicated by massive postoperative haemorrhage. The administration of recombinant activated Factor VII was associated with improved haemostasis. However, development of cardiac tamponade soon after injection required emergency exploration and evacuation of a large mediastinal clot.
HednerU.Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.Thromb Haemost1999; 82: 531–539.
4.
KeyN.S., AledortL.M., BeardsleyD.Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.Thromb Haemost1998; 80: 912–918.
5.
WhiteB., O'ConnorH., SmithO.P.Successful use of recom-binant factor VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.Blood Coagul Fibrinolysis2000; 11: 155–157.
6.
CheungP.Y., SawickiG., SalasE., EtchesP.C., SchulzR., RadomskiM.W.The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates.Crit Care Med2000; 28: 2584–2590.
7.
NapoliV.M., SymbasP.J., VroonD.H., SymbasP.N.Auto-transfusion from experimental hemothorax: levels of coagulation factors.J Trauma1987; 27: 296–300.
8.
HolleuferR.F., Von BormannB.Continuous autotransfusion system (CATS-Fresenius) Vs Dideco autotransfusion system (Autotrans-Dideco). First clinical results with a new continuous operating autotransfusion device in vascular surgery.Br J Anaesth1995; 74: Suppl 1: A64.
9.
SieunarineK., Lawrence-BrownM.M.D., GoodmanM.A., PrendergastF.J., RocchettaS.Plasma levels of the lipid mediators, leukotriene B4 and lyso platelet-activating factor, in intraoperative salvaged blood.Vox Sang1992; 63: 168–171.
10.
HednerU.NovoSeven as a universal haemostatic agent.Blood Coagul Fibrinolysis2000; 11: Suppl 1: S107–111.
11.
MakrisM., WatsonH.G.The management of coumarin-induced over-anticoagulation.Br J Haematol2001; 114: 271–280.
12.
PuetzJ.J., BouhasinJ.D.Use of recombinant factor VIIa to control bleeding in an adolescent male with severe hemophilia A, HIV, thrombocytopenia, hepatitis C and end-stage liver disease.Am J Hosp Palliat Care2002; 19: 277–282.
13.
MoisescuE., ArdeleanL., SimionI., MuresanA., CiupanR.Recombinant factor VIIa treatment of bleeding associated with acute renal failure.Blood Coagul Fibrinolysis2000; 11: 575–577.
14.
SlappendelR., HuversF.C., BenraadB., NovakovaI., van HellemondtG.G.Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.Anesthesiology2002; 96: 1525–1527.
15.
HendriksH.G., van der MaatenJ.M., de WolfJ.An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII.Anesth Analg2001; 93: 287–289.
16.
LismanT., LeebeekF.W., MeijerK., Van Der MeerJ., NieuwenhuisH.K., De GrootP.G.Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation.Hepatology2002; 35: 616–621.
17.
TarantinoM.D., AberleR.Recombinant factor VIIa (Novo-Seven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease.Am J Hematol2001; 68: 62–63.
18.
MartinowitzU., KenetG., SegalE.Recombinant activated factor VII for adjunctive hemorrhage control in trauma.J Trauma2001; 51: 431–438.
19.
MartinowitzU., HolcombJ.B., PusateriA.E.Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.J Trauma2001; 50: 721–729.
